報價延遲最少15分鐘:2026/01/08 17:09 EST
盤後時段
|
||||
|
3.21 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.15
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-25.59/-3.92
|
|
企業價值
121.37M
|
| 資產負債 |
|
每股賬面淨值
-1.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib. |
